What was recalled
This page synthesizes the strain-specific clinical evidence framework around Bifidobacterium animalis subsp. lactis BB-12 in commercial pet food. BB-12 is a commercial probiotic strain owned by Chr. Hansen Holding A/S (Denmark), recently merged with Novozymes to form Novonesis in 2024. The strain originated from a 1985 dairy fermentation isolate and has since been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) under accession DSM 15954. BB-12 is one of the most-commercialized probiotic strains globally, used across human dairy fermentation (yogurt, fermented milk drinks), dietary supplements (capsules, powders), infant formula, and commercial pet food. The strain is on the AAFCO-compatible Generally Recognized As Safe (GRAS) inventory through the FDA notification process, and on the European Food Safety Authority QPS (Qualified Presumption of Safety) list for use in animal feed.
The human clinical evidence base spans approximately 200 peer-reviewed publications over a 30+ year window. Documented effects include: (i) gut microbiota modulation — increases in fecal Bifidobacterium counts, modest reductions in opportunistic pathogen counts (Clostridium difficile, Enterobacteriaceae), with effect persistence typically 1-4 weeks post-discontinuation; (ii) immune-cell modulation — documented effects on peripheral blood lymphocyte subsets (CD4+/CD8+ ratios), serum and secretory IgA concentrations, and innate immune markers; (iii) stool-quality endpoints — Bristol Stool Scale shifts toward type 4 in healthy adults, modest reductions in diarrhea incidence in pediatric and adult populations; (iv) antibiotic-associated diarrhea (AAD) prevention — multiple RCTs document reduced AAD incidence with co-administered BB-12 during antibiotic courses; (v) respiratory infection incidence reduction — documented effects in pediatric daycare cohorts and adult cohorts.
The companion-animal trial evidence is substantially thinner. A literature search yields approximately 10-20 published trials specifically in dogs (Canis lupus familiaris) and cats (Felis catus) using BB-12 either as a single strain or as part of multi-strain formulations. Documented effects in companion animals include: (i) increased fecal Bifidobacterium counts (Garrigues 2010 in healthy adult dogs); (ii) improved stool consistency in dogs with mild gastrointestinal upset (Schmitz 2014); (iii) reduced enterotoxin shedding in cats co-housed with affected animals (Bybee 2011, primarily Enterococcus faecium SF68 with BB-12 as adjunct); (iv) modest effects on serum cytokine profiles in healthy adult dogs (Marshall-Jones 2006, primarily SF68 with BB-12 in some formulations). The companion-animal evidence is generally consistent with the human evidence direction but represents a substantially smaller dataset.
Why it was recalled
The structural concerns have three layers. Layer one — evidence-quality conflation between species: pet food marketing claims around BB-12 frequently cite the human evidence base (200+ trials, multiple meta-analyses, multiple regulatory authority endorsements) without specifying that the cited evidence is in humans rather than the target species. Companion animal owners reading product marketing may reasonably infer that the BB-12 evidence base is equally robust in dogs and cats, which the available trial literature does not support. The structural conflation is not unique to BB-12 — most pet food probiotic marketing cites cross-species evidence — but BB-12 is a frequent example because its human evidence base is unusually strong.
Layer two — strain-specific evidence does not transfer across strains: probiotic effects are highly strain-specific. BB-12 evidence does not apply to other Bifidobacterium animalis strains (e.g., Bifidobacterium animalis subsp. animalis or other subsp. lactis strains like DN-173 010 from Danone). Pet food labels typically list ingredient names at the species level ("Bifidobacterium animalis") without specifying which strain or which proprietary source. Consumer-facing identification of whether a specific pet food contains BB-12 specifically (versus a different B. animalis strain with different evidence) is typically not possible from the label alone. Brand customer service may or may not disclose strain-level sourcing.
Layer three — CFU labeling does not convey strain efficacy: pet food probiotic labeling typically lists CFU (colony-forming unit) count at time of manufacture and a guarantee through a defined shelf life. The CFU count does not convey strain-specific efficacy. A diet containing 1 billion CFU/kg of a well-studied strain like BB-12 may produce substantively different in-vivo effects than a diet containing 10 billion CFU/kg of a poorly-characterized strain. The label cannot easily convey this evidence-quality difference. The framework is covered in additional depth at our probiotic strain viability controversy page.
Health risks for your pet
BB-12 safety profile in companion animals is generally favorable. The strain carries QPS status with EFSA and GRAS status with FDA, with no documented adverse events in published companion-animal trials at typical commercial dosing (10^6 to 10^9 CFU/g of food). The strain is not pathogenic in healthy or immunocompromised animals at reasonable doses. Theoretical safety considerations for any probiotic include: (i) bacteremia or sepsis in severely immunocompromised animals (rare; documented case reports in human medicine involve Lactobacillus rhamnosus GG more than Bifidobacterium); (ii) D-lactic acidosis in animals with short bowel syndrome (rare; primarily relevant to specific Lactobacillus strains, not Bifidobacterium); (iii) transient bloating, flatulence, or stool consistency change during initial supplementation (common, typically resolves within 1-2 weeks); (iv) interaction with concurrent antibiotic therapy (probiotic CFU counts drop substantially during antibiotic courses, which is why probiotics are typically continued for 1-2 weeks post-antibiotic course).
The health-outcome concerns for pet owners relying on BB-12-containing pet food are primarily evidence-quality rather than safety. If a pet owner is seeking a probiotic intervention for a specific health goal (chronic enteropathy management, antibiotic-associated diarrhea prevention, acute diarrhea support, immune-modulation in geriatric pets, allergy adjunct), the BB-12 companion-animal evidence base may not support the same effect size as the human evidence base suggests. Veterinarians experienced in nutrition typically recommend probiotic strains with companion-animal-specific trial evidence (Enterococcus faecium SF68 at the strongest evidence tier, Bifidobacterium longum BL999, multi-strain veterinary-targeted formulations) over strains with primarily human evidence.
What to do if you bought affected product
Pet owners interested in BB-12-containing pet food can navigate the evidence framework meaningfully through several practical approaches: (1) distinguish strain-level evidence from species-level evidence — BB-12 is a specific strain (DSM 15954, Chr. Hansen); pet food labeling typically lists "Bifidobacterium animalis" at the species level without strain specification, and you may need to contact the brand customer service to confirm whether the product contains BB-12 specifically or a different B. animalis strain; (2) look for veterinary-evidence-tier products if you have a specific health goal — FortiFlora (Enterococcus faecium SF68), Proviable (multi-strain), Visbiome Vet, and similar veterinary-targeted products carry stronger companion-animal-specific evidence than most commercial-food-included probiotics; (3) request CFU-at-end-of-shelf-life data from brand customer service — pet food probiotics lose viability across shelf life; CFU at time of manufacture may differ substantially from CFU at end of shelf life, and the latter is what your pet actually consumes; (4) treat probiotic-fortified kibble as a baseline intervention, not a therapeutic dose — if your pet has a specific gastrointestinal condition, a targeted veterinary-tier probiotic supplement at therapeutic dose (typically 10^9 to 10^10 CFU/dose) usually outperforms baseline probiotic-fortified kibble (typically 10^6 to 10^8 CFU/feeding); (5) consult with your veterinarian for specific GI conditions — chronic enteropathy, inflammatory bowel disease, antibiotic-associated diarrhea, and other GI conditions benefit from strain-specific evidence-based selection rather than label-marketing-driven selection; (6) treat BB-12 as evidence-supported in human nutrition with extrapolation-quality evidence in companion animals — the strain is safe and likely useful, but the marketing typically overclaims the strain-specific companion-animal evidence; (7) watch label claim language carefully — "contains probiotics" or "with live cultures" without specific strain identification typically signals lower evidence quality than products that specify strain identity, CFU count at end of shelf life, and the trial evidence base supporting the specific strain.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate probiotic strain identity in scoring per our published methodology, since strain identity is rarely disclosed on pet food labels and the evidence-quality framework is not visible to a label-based rubric. Future rubric extension under consideration: brands publishing strain-specific identification (DSM, ATCC, or proprietary accession numbers), CFU-at-end-of-shelf-life guarantees, and companion-animal-specific trial citations would receive favorable scoring weight as transparency signals. The broader probiotic framework is covered across our probiotic strain viability controversy, Bifidobacterium animalis explainer, and related strain explainer pages. For now, our recommendation: treat BB-12 as evidence-supported in human nutrition with safety-cleared use in companion animals, but expect strain-specific companion-animal efficacy data to be substantially thinner than marketing language implies.